Paul Hartmann (PHH2) Q4 2023 earnings summary

Executive summary

• 2023 revenue reached €2,353.3 million, with 2.3% organic growth; adjusted EBITDA rose to €203.4 million, above the initial outlook and prior year.

• Transformation measures contributed more than €50 million to adjusted EBITDA and helped offset nearly €60 million of higher material and energy costs, plus rising personnel costs.

• Growth in Wound Care, Incontinence Management and Complementary Divisions was offset by an 8.0% organic sales decline in Infection Management.

Financial highlights

• Revenue increased 1.8% to €2,353.3 million; organic growth was 2.3%, currency effects were -0.7% and acquisitions/divestments contributed +0.2%.

• Adjusted EBITDA rose to €203.4 million from €190.8 million; adjusted EBITDA margin improved to 8.6% from 8.3%.

• EBITDA was €165.5 million versus €165.0 million; EBIT was €62.5 million versus €63.4 million.

• Net income declined to €32.7 million from €39.5 million; EPS was €8.00 versus €10.18. Net finance expense increased to €13.6 million from €2.8 million.

• Restructuring charges were €24.0 million, mainly for Wound Care production relocation and KNEIPP modernization; other adjustments of €13.8 million mainly related to SAP S/4HANA and legacy legal cases.

Outlook and guidance

• 2024 guidance calls for moderate organic revenue growth and adjusted EBITDA of €200–240 million, subject to stated assumptions and risk factors.

• Transformation measures are expected to contribute nearly €50 million to 2024 results; planned 2024 investment is ~€170 million.

• The 2024 outlook anticipates a challenging European healthcare market, continued price pressure and difficult hospital conditions; modern wound-care products offer stronger growth prospects than traditional products.